|
| 37904069 | Independent Advice on Drug Approvals: an Investigation of EMA Practices. | J Gen Intern Med | 2024 |
| 36734878 | A "Method of Use" to Prevent Generic and Biosimilar Market Entry. | N Engl J Med | 2023 |
| 37991784 | Outcomes of the 340B Drug Pricing Program: A Scoping Review. | JAMA Health Forum | 2023 |
| 37871317 | Changes in Induced Medical and Procedural Abortion Rates in a Commercially Insured Population, 2018 to 2022 : An Interrupted Time-Series Analysis. | Ann Intern Med | 2023 |
| 37410756 | Physician experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use. | PLoS One | 2023 |
| 36858453 | US public investment in development of mRNA covid-19 vaccines: retrospective cohort study. | BMJ | 2023 |
| 36441536 | Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare Savings. | JAMA Intern Med | 2023 |
| 36877723 | Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures. | PLoS Med | 2023 |
| 34337777 | Regulatory authority and clinical acceptability: Physicians' responses to regulatory drug safety warnings. | Br J Clin Pharmacol | 2022 |
| 35438459 | Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study. | Drug Saf | 2022 |
| 35500185 | Unwanted Advice? Frequency, Characteristics, And Outcomes Of Negative Advisory Committee Votes For FDA-Approved Drugs. | Health Aff (Millwood) | 2022 |
| 35426909 | Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability. | JAMA | 2022 |
| 35487821 | State Laws and Generic Substitution in the Year After New Generic Competition. | Value Health | 2022 |
| 36568649 | Mifepristone, preemption, and public health federalism. | J Law Biosci | 2022 |
| 35867550 | Industry Payments to Physicians Are Kickbacks. How Should Stakeholders Respond? | J Health Polit Policy Law | 2022 |
| 35894560 | High-Priced Sickle Cell Gene Therapies Threaten to Exacerbate US Health Disparities and Establish New Pricing Precedents for Molecular Medicine. | J Law Med Ethics | 2022 |
| 36125474 | Risks to the 340B Drug Pricing Program-Reply. | JAMA | 2022 |
| 35984350 | Improving the Use of FDA Advisory Committees. | N Engl J Med | 2022 |
| 35877952 | The Bayh-Dole Act at 40: Accomplishments, Challenges, and Possible Reforms. | J Health Polit Policy Law | 2022 |
| 34890560 | COVID-19 antivirals must not affect HIV drug supply. | Lancet HIV | 2022 |
| 35015587 | Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling. | J Clin Oncol | 2022 |
| 35043019 | The characteristics of patents impacting availability of biosimilars. | Nat Biotechnol | 2022 |
| 35211322 | Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases. | J Law Biosci | 2022 |
| 35058332 | Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis. | BMJ Qual Saf | 2022 |
| 35201276 | Updating the Bayh-Dole Act: March-in Rights and Transparency. | JAMA | 2022 |
| 35050352 | Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use. | JAMA Netw Open | 2022 |
| 35020981 | State Restrictions on Mifepristone Access - The Case for Federal Preemption. | N Engl J Med | 2022 |
| 34748375 | COVID-19 Vaccine Boosters for All Adults: An Optimal U.S. Approach? | Ann Intern Med | 2022 |
| 34045279 | Civil commitment for opioid misuse: do short-term benefits outweigh long-term harms? | J Med Ethics | 2022 |
| 32865564 | Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions. | JAMA Intern Med | 2021 |
| 33492341 | Substitution of Generic Drugs and Biosimilars-Reply. | JAMA Intern Med | 2021 |
| 33904111 | A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs. | Drug Saf | 2021 |
| 33846649 | Identifying potential prescription drug product hopping. | Nat Biotechnol | 2021 |
| 33779681 | Frequency of First Generic Drug Approvals With "Skinny Labels" in the United States. | JAMA Intern Med | 2021 |
| 34661600 | Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D. | JAMA Intern Med | 2021 |
| 34779852 | Promoting Biosimilar Competition by Revising Medicare Reimbursement Rules. | JAMA Netw Open | 2021 |
| 34481596 | The implications of Industry-Funded Disease Awareness Campaigns in the Rare Disease Setting. | Mayo Clin Proc | 2021 |
| 33966663 | INTRODUCTION: Public Sector and Non-Profit Contributions to Drug Development - Historical Scope, Opportunities, and Challenges. | J Law Med Ethics | 2021 |
| 33966649 | A Non-Profit Approach to Address Foreign Dependence of Generic Drugs. | J Law Med Ethics | 2021 |
| 33939506 | Diabetes Drugs: List Price Increases Were Not Always Reflected In Net Price; Impact Of Brand Competition Unclear. | Health Aff (Millwood) | 2021 |
| 34145566 | Cost to Medicare of Delayed Adalimumab Biosimilar Availability. | Clin Pharmacol Ther | 2021 |
| 34339242 | Barriers To US Biosimilar Market Growth: Lessons From Biosimilar Patent Litigation. | Health Aff (Millwood) | 2021 |
| 33085508 | Ensuring Safe Access to Mifepristone During the Pandemic and Beyond. | Ann Intern Med | 2021 |
| 33252639 | Corrections to Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions. | JAMA Intern Med | 2021 |
| 33308347 | Preventing medical-device-borne outbreaks: High-level disinfection policy for duodenoscopes. | Infect Control Hosp Epidemiol | 2021 |
| 33206339 | Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program. | Drug Saf | 2021 |
| 32767557 | Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States. | Clin Pharmacol Ther | 2021 |
| 31613694 | Right to Try Requests and Oncologists' Gatekeeping Obligations. | J Clin Oncol | 2020 |
| 31910271 | Changes in Utilization of Generic Angiotensin Receptor Blockers Following Product Recalls in the United States. | JAMA | 2020 |
| 31872419 | Comparative Outcomes of Treatment Initiation With Brand vs. Generic Warfarin in Older Patients. | Clin Pharmacol Ther | 2020 |